Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alsin Rho guanine nucleotide exchange factor ALS2 is a multidomain protein encoded by the ALS2 gene that serves as a guanine nucleotide exchange factor (GEF) for small GTPases, primarily Rab5 and Rac1. Alsin is highly expressed in the central nervous system, especially in motor neurons of the brain and spinal cord, where it regulates endosomal trafficking, cytoskeletal remodeling, and neuronal outgrowth. Disruption of ALS2 function through gene mutation causes inherited neurodegenerative syndromes including juvenile-onset amyotrophic lateral sclerosis (ALS2), infantile-onset ascending hereditary spastic paralysis, and juvenile primary lateral sclerosis. These disorders manifest as progressive muscle weakness and degeneration of upper motor neurons, thought to arise from defects in endocytic vesicle processing, receptor recycling, and cytoskeletal maintenance, for which alsin is essential. There are currently no known direct pharmacological therapies targeting ALS2, and its major relevance is in neurogenetic diagnostics and disease pathogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alsin Rho guanine nucleotide exchange factor ALS2 (ALS2).